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Brucella enters their hosts mostly through mucosae from where it spreads systemically.
Adhesion to extracellular matrix (ECM) components or to host cells is important for the
infectious process, and is mediated by several adhesins, including the BtaF trimeric
autotransporter. Although Th1 responses and gamma interferon (IFN-γ) are important for
protection, antibodies able to block adhesions might also contribute to prevent Brucella
infection. We evaluated the importance of BtaF for respiratory Brucella infection, and
characterized the immune response and protection from mucosal challenge induced by
nasal vaccination with recombinant BtaF. While lung CFU numbers did not differ at day
1 p.i. between mice intratracheally inoculated with B. suis M1330 (wild type) and those
receiving a 1btaF mutant, they were reduced in the latter group at 7 and 30 days p.i.
For vaccination studies the BtaF passenger domain was engineered and expressed as
a soluble trimeric protein. Mice were immunized by the nasal route with BtaF or saline
(control group) plus the mucosal adjuvant c-di-AMP. Specific anti-BtaF antibodies (IgG
and IgA) were increased in serum, including a mixed IgG2a/IgG1 response. In vitro,
these antibodies reduced bacterial adhesion to A549 alveolar epithelial cells. Specific IgA
antibodies were also increased in several mucosae. Spleen cells from BtaF immunized
mice significantly increased their IL-2, IL-5, IL-17, and IFN-γ secretion upon antigen
stimulation. In cervical draining lymph nodes, antigen-experienced CD4+ T cells were
maintained mainly as central memory cells. A BtaF-specific delayed-type hypersensitivity
response was detected in BtaF immunized mice. Lung cells from the latter produced
high levels of IFN-γ upon antigen stimulation. Although nasal immunization with BtaF did
not protect mice against B. suis respiratory challenge, it conferred significant protection
from intragastric challenge; the splenic load of B. suis was reduced by 3.28 log CFU in
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immunized mice. This study shows that nasal vaccination with BtaF+c-di-AMP protects
against intragastric challenge with B. suis by inducing local and systemic antibody
responses, central memory CD4+ T cells and strong Th1 responses. Therefore, although
BtaF vaccination did not protect fromB. suis respiratory infection, this adhesin constitutes
a promising immunogen against mucosal B. suis infection.
Keywords: Brucella suis, bacterial adhesins, BtaF autotransporter, respiratory infection, nasal immunization,
mucosal immunity, intragastric challenge
INTRODUCTION
Brucellosis is a zoonotic disease caused by bacteria of the
genus Brucella, a Gram-negative pathogen, which affects 500,000
new people annually in the world (1, 2). In domestic animals
Brucella causes abortion and infertility and leads to important
economic losses. In contrast, human brucellosis is a debilitating
disease which can evolve with chronic complications such as
osteoarticular disease, meningitis, and endocarditis. Human
infection can be acquired by consumption of raw meat or non-
pasteurized dairy products, inhalation of infected aerosols or
contact with infected animal products through conjunctiva or
skin lesions (3, 4). Because of its high infectivity by the inhalatory
route (5–10) Brucella has been included in the list of possible
bioterrorism agents by the Centers for Disease Control and
Prevention (CDC) (1). The entry by mucosal membranes is also
important in domestic animal infection, not only by the routes
already described but also by the venereal route.
Brucella suis is the etiological agent of swine brucellosis
and one of the main human brucellosis pathogens. As the
human infection is frequently acquired from animal sources, the
diagnosis and vaccination of livestock are fundamental strategies
to prevent human disease. However, currently there are no
commercially available vaccines for use in human and swine
in most countries, except in China where an attenuated strain
(B. suis S2) is used for swine vaccination (11). Although initial
reports were promising, this vaccine has not been tested in other
countries. Moreover, as B. suis S2 is a smooth strain it induces an
antibody response that precludes the serological discrimination
between vaccinated and infected animals using conventional
tests (12).
On the other hand, commercially available Brucella vaccines
approved for use in cattle, goats, and sheep are based on
attenuated strains, which can still produce disease in humans
(13–15). In addition, they may result in abortion when
administered to pregnant females, and can induce immune
responses that interfere with serological diagnosis. Therefore,
improved vaccines that combine safety and efficacy and can
protect all susceptible animal species need to be developed (16).
Acellular vaccines, such as those based on recombinant proteins,
offer numerous advantages over attenuated vaccines. They are
safe, well-defined, non-infectious, and cannot become virulent.
However, they are frequently poorly immunogenic and require
the use of adjuvants. The selection of appropriate antigens based
on the knowledge about the host-pathogen interaction is essential
for the success of these vaccines.
Brucella enters the host mostly through mucous membranes
from where it spreads systemically to different organs, causing
the symptoms of the disease. Adhesion of Brucella to extracellular
matrix (ECM) components or to host cells is an important step
for the infection (17–19). It was proposed that the binding of
Brucella to host cells is mediated by molecules containing sialic
acid and/or sulphated residues, and by components of the ECM
such as fibronectin, collagen, and vitronectin (17, 18). Recently,
we have identified several adhesins that are involved in the
adhesion of B. suis to ECM components and host cells (19–
21). One of such adhesins, the BtaF trimeric autotransporter,
was involved in the adhesion to various ECM components
and to human cervical (HeLa) and alveolar (A549) epithelial
cells. In addition, BtaF was required for full virulence during
intragastric infection in mice (20). The trimeric autotransporters
are a subclass of the type V secretion systems (22, 23). They have a
C-terminal domain that forms a β-barrel in the outer membrane
of gram-negative bacteria, and a surface-exposed passenger (and
functional) domain that predominantly forms a coiled-coil fiber
(α-domain) and extends the adhesive N-terminal head from
the bacterial surface (24). The adhesins, in particular those of
the autotransporter families, represent attractive targets for the
design of novel vaccines directed against Gram-negative bacteria
(25). However, the role of the BtaF adhesin in the infection and
dissemination of B. suis after the respiratory infection, and its
potential as an immunogen in acellular mucosal vaccines against
B. suis are currently unknown.
Since Brucella are intracellular facultative pathogens that
establish their preferred replicative niche in macrophages (26,
27), the protective immune response against these bacteria is
mainly mediated by T helper type 1 (Th1) cells that secrete
gamma interferon (IFN-γ), which upregulates macrophage
anti-Brucella activity. It has also been shown that antibodies
contribute to protection against respiratory Brucella infection
(28, 29). In particular, the induction of antibodies able
to block the initial stages of infection, such as bacterial
attachment to host cell components or to the ECM of the
mucosal surface, might represent an attractive strategy to
prevent Brucella infection. Therefore, while the induction of
systemic immune responses following immunization represents
a major goal for the ideal vaccine against brucellosis, the
elicitation of a specific mucosal immune response would help
to prevent pathogen entry and dissemination to other organs.
To achieve this, antigens must be administered through the
mucosal route with appropriate mucosal adjuvants, such as
cyclic di-nucleotides.
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The cyclic di-nucleotides are second-messenger molecules in
bacteria that are sensed by the host vía STING (stimulator of
interferon genes) receptors, which in turn trigger several immune
responses. One of these cyclic nucleotides, bis-(3′,5′)- cyclic
dimeric adenosine monophosphate (c-di-AMP), has been widely
shown to exert strong adjuvant activities when it is used in
mucosal vaccine formulations (30–34).
Nasal vaccination usually induces appropriate antigen-specific
responses not only in nasal mucosa but also in other mucosal
sites, thus protecting the individual from infection through
several mucosal routes. Despite the potential advantages of
mucosal immunization, very few studies have evaluated the nasal
route of vaccination against Brucella mucosal challenge. In most
of these studies attenuated strains were tested, and the results
were discouraging (28, 35). To our best knowledge, no studies
have been published assessing the efficacy of nasal vaccination
with acellular vaccines against mucosal challenge with B. suis.
In this study, we evaluated the importance of the BtaF adhesin
for respiratory Brucella infection, and characterized the immune
response elicited by nasal vaccination with recombinant BtaF
plus c-di-AMP and the protection conferred against mucosal
challenge with B. suis.
MATERIALS AND METHODS
Animals
Female BALB/c mice (6–8 weeks old) were purchased from
Universidad Nacional de La Plata, Argentina, acclimated and
randomly distributed into experimental groups. The animals
were housed in a biosafety level 3 animal facility (Unidad
Operativa Centro de Contención Biológica, Administración
Nacional de Laboratorios e Institutos de Salud Dr. Carlos
G. Malbrán, Argentina), and received water and food
ad libitum. Experiments in mice were approved by the
animal care and use committee of Facultad de Farmacia
y Bioquímica, Universidad de Buenos Aires (CICUAL D
N◦ 3300/18).
Bacterial Strains, Culture Conditions, and
Media
Brucella suis M1330 (wild-type strain, wt), B. suis 1btaF
and B. suis 1btaF complemented with the btaF gene were
grown in Tryptic Soy Broth (TSB, BactoTM) at 37◦C with
agitation (20). When necessary, chloramphenicol (6µg/ml) and
nalidixic acid (10µg/ml) were added. Bacteria were washed
with sterile phosphate buffered saline (PBS) and inocula were
prepared on the basis of optical density (OD) readings. The
actual number of colony forming units (CFU) was later
determined by plating on Tryptic Soy Agar (TSA, BactoTM). All
live Brucella manipulations were performed in biosafety level
3 facilities.
Escherichia coli strains used in this study, DH5α and
BL21 (DE3) pLysS, were grown with agitation at 37◦C in
Luria-Bertani (LB) medium supplemented with kanamycin
(25 µg/ml).
Kinetics of B. suis Infection in a
Respiratory Model
Groups of 5 female BALB/c mice were inoculated intratracheally
with B. suis M1330 (5 × 104 CFU/mice) as previously described
(36) withminormodifications. Briefly, animals were anesthetized
with isoflurane and after becoming recumbent, they were injected
intraperitoneally with a mixture of ketamine and xylazine
(100 and 10 mg/kg, respectively). Mice were placed in supine
position over an acrylic backboard and restrained by the
teeth using a rubber band. Under translucent illumination of
the trachea, the inoculum was injected in a final volume of
20 µl in between the vocal cords with a Hamilton syringe
coupled to a blunt-ended probe. Mice were euthanized at
1, 7, and 30 days post-infection (p.i.) by an intraperitoneal
injection of a lethal dose of ketamine and xylazine, and their
spleens, livers and lungs were aseptically removed. The whole
organs were homogenized in 2ml of sterile PBS, and serial
dilutions of homogenate aliquots were plated on TSA for
CFU counting.
Virulence of B. suis btaF Mutant
Groups of 15 female BALB/cmice were inoculated intratracheally
with 5 × 104 CFU/mice of the B. suis strains described
above (wt, 1btaF, or complemented 1btaF). Five mice from
each group were euthanized at 1, 7, and 30 days p.i. by
an intraperitoneal injection of a lethal dose of ketamine and
xylazine, and their spleens, livers, and lungs were aseptically
removed and homogenized in 2ml of sterile PBS. Serial




All DNA manipulations were carried out using standard
procedures. To construct the BtaF trimeric recombinant protein,
part of the BtaF passenger domain coding sequence (BR1846)
was amplified using B. suis M1330 genomic DNA as template,
and primers BtaF_PD_F and BtaF_PD_Sint_R (5′-CTTTAA
GAAGGAGATATACATATGGAGGAAAATGTTTCGCAG
GTGAAACT-3′ and 5′-TCTGTTTCATGCGACCGCGGTT
TTGGC-3′, respectively), thus obtaining a PCR product of
535 bp. Secondly, the GCN4tri-His sequence was amplified
using plasmid pIBA-GCN4tri-His as template (37), and primers
BtaF_PD_Sint_F and BatF_PD_R (5′-CCGCGGTCGCATG
AAACAGATTGAAG-3′ and 5′-CGGGCTTTGTTAGCAGC
CGGATCGTCGACTCAGTGATGATGATGATGATGAAG
C-3′, respectively), thus obtaining a PCR product of 153 bp.
Subsequently, both fragments (containing complementary
regions) were ligated by overlapping PCR using the flanking
oligonucleotides (BtaF_PD_F and BtaF_PD_R). The resulting
fragment of 688 bp was used as a megaprimer in a PCR reaction
with the pET-24a expression plasmid (Novagen) as template
according to the restriction-free cloning method (38). Then,
the PCR reaction product was digested with DpnI at 37◦C
for 2 h and the mixture was transformed into E. coli DH5α
competent cells. Selection was carried out on LB-kanamycin
plates, and the resulting plasmid (pET-BtaF-GCN4tri-His) was
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isolated. This construct was checked by sequencing. Finally, the
pET-BtaF-GCN4tri-His plasmid was transformed into E. coli
BL21 (DE3) pLysS competent cells.
BtaF Recombinant Protein Purification
Precultures of E. coli BL21 (DE3) pLysS bearing the pET-BtaF-
GCN4tri-His plasmid were grown overnight in 5ml of LB
supplemented with 25µg/ml kanamycin at 37◦C with agitation
(200 r.p.m.), and then diluted to 500ml and grown until an
OD600 of 0.6. At this point, protein expression was induced by
the addition of isopropyl-thio-β-D-galactopyranoside (IPTG) to
a final concentration of 0.5mM, and incubation was continued
for 4 h at 37◦C. Cells were harvested by centrifugation at
16,000 × g for 10min at 4◦C, resuspended in binding buffer
(20mM Na phosphate buffer pH 7.4, 500mM NaCl, 20mM
imidazole, 1mM phenylmethylsulphonylfluoride—PMSF) and
disrupted by sonication with a probe tip sonicator (QSonica-
LLC, Q500), keeping bacteria on ice. Total cell lysate was
centrifuged at 100,000 × g for 45min at 4◦C in a Beckman
Coulter L7-65 ultracentrifuge, and the supernatant was filtrated
by a 0.2µm syringe filter. Then, it was loaded onto a HisTrapTM
HP column (GE Healthcare) and elution was performed with
a linear gradient of elution buffer (20mM Na phosphate buffer
pH 7.4, 500mM NaCl, 500mM imidazole). Purification was
carried out following protein absorbance at 220 nm. A major
peak was observed. The appropriate fractions were pooled
and dialyzed overnight at 4◦C against S200 buffer (20mM Na
phosphate buffer pH 7.4, 300mM NaCl). The BtaF trimeric
recombinant protein was further purified by Superdex 200
prep grade (GE Healthcare) in S200 buffer. The appropriate
fractions were pooled and dialyzed overnight at 4◦C against
PBS. The quality of the final preparation was checked by
SDS-PAGE (15% gel) followed by Coomassie Blue Staining.
In order to separate the trimer, an aliquote of the purified
protein was mixed with Laemmli sample buffer containing
3M urea. Immunogenicity of the recombinant protein in mice
was tested by Western blot. Briefly, purified BtaF recombinant
protein was subjected to SDS-PAGE (15% gel) and transferred
to a Hybond PVDF membrane (Amersham, GE Healthcare).
Membrane was blocked with TBS 5% milk powder (w/v) with
gentle agitation for 1 h at room temperature, and then probed
with pooled sera from BtaF-immunized mice (see the following
section), at a 1:2,000 dilution in TBS-Tween 0.05 and 1%
milk, with gentle agitation at 4◦C for 16 h. Membrane was
then incubated with goat HRP-conjugated anti-mouse (1:30,000)
secondary antibody (Santa Cruz) in TBS-Tween 0.05 and 1%
milk, with gentle agitation at room temperature for 2 h. The blot
was developed using ECL Prime (Amersham, GE Healthcare)
following the manufacturer’s instructions, and was imaged using
an ImageQuant LAS4000 Molecular Imager (GE Healthcare).
Protein folding was confirmed by Circular Dichroism (CD
Spectrometer Jasco J-815). The theoretical molecular weight of
the trimer, 66.6 kDa, was predicted using the ProtParam tool
from ExPASy (39). The molecular weight of the native protein
in solution was confirmed by Static Light Scattering (Precision
Detectors PD2010 90◦ light scattering instrument) tandemly
connected to a high-performance liquid chromatography, a
LKB 2142 differential refractometer, and to a 486 Absorbance
Detector (Waters) set at 220 nm. The purified protein (500
µl, ∼0.5 mg/ml) was loaded into a Superdex 75 GL 10/300
(GE Healthcare) column, and the chromatographic run was
performed in Phosphate Buffer Saline pH 7.4 and 250mM
sodium chloride under isocratic conditions at a flow rate of 0.4
ml/min at 20◦C (room temperature). The molecular weight was
calculated by relating its 90◦ and RI signals and comparison
of this value with the one obtained for bovine serum albumin
(BSA, molecular mass: 66.5 kDa) as a standard using the software
Discovery32.The purified protein was incubated with polymyxin
B-Sepharose (Thermo Fisher Scientific, Massachusetts, USA)
overnight at 4◦C with agitation to eliminate lipopolysaccharide
(LPS) contamination. The protein concentration of the antigen
preparations was determined by the bicinchoninic acid method
(Pierce, Rockford, IL) using BSA as standard. All BtaF
preparations used contained <0.1 endotoxin units per mg
of protein.
Nasal Immunization
To evaluate the effect of nasal vaccination with the BtaF protein,
3′5′-c-di-AMP (c-di-AMP) (InvivoGen, California, USA) was
used as a mucosal adjuvant. Mice were divided into two
groups (n = 5) and were immunized once a week for 3
weeks by nasal instillation with BtaF (10 µg) plus c-di-AMP
(10 µg), or saline plus c-di-AMP (10 µg) in a final volume
of 20 µl. Immunization times were selected on the basis
of previous studies (40, 41). At 0 and 21 days, after the
first immunization, serum samples were obtained to evaluate
levels of specific anti-BtaF antibodies. One week after last
immunization, saliva, feces, bronchoalveolar lavage fluid (BAL),
FIGURE 1 | Kinetics of intratracheal infection with B. suis. BALB/c mice were
infected with 5 × 104 CFU/mice of B. suis wt. At 1, 7 and 30 days
post-infection mice were euthanized, and the lungs, spleens, and livers were
removed. Dilutions of organs homogenates were plated and CFU were
counted. Values are means ± SD of duplicate measurements from three
independent experiments. Asterisks indicate significant differences between 1
and 7 days and up arrowheads and crosses significant differences between 7
and 30 days. ****p < 0.0001; ∧∧∧p < 0.001; ++++p < 0.0001.
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vaginal lavage fluid, lung homogenates, and spleens were
obtained for immunological studies.
Determination of Antibody Response
BtaF specific antibodies were measured by indirect ELISA.
Specific IgG, IgG1, IgG2a, and IgA antibodies were determined
in serum samples obtained at 0 and 21 days after the first
immunization, and specific IgA was measured in saliva, feces,
BAL, vaginal lavage fluid, and lung homogenates. In all cases,
polystyrene plates (Corning Incorporated, New York, USA) were
coated with purified BtaF recombinant protein (0.5 µg/well) in
PBS during 1 h at 37◦C. After this incubation, plates were washed
three times with PBS containing 0.05% Tween-20 (PBS-T) and
blocked overnight at 4◦C with 200 µl of PBS containing 3%
of skim milk. Plates were incubated with appropriate dilutions
of the different samples for 2 h at room temperature and then
were washed three times with PBS-T. Isotype-specific goat
anti-mouse horseradish peroxidase conjugates (Sigma Aldrich,
Missouri, USA; Jackson ImmunoResearch, Pennsylvania, USA)
were added at appropriate dilutions. After 1 h of incubation
at 37◦C, plates were washed three times and TMB substrate
solution (BD TMB Substrate Reagent Set, BD Bioscience, San
Diego, USA) was added to each well. After 15min of incubation
at room temperature, the reaction was stopped by the addition
of 2N H2SO4, and the OD was measured at 450 nm in a
microplate reader (Multiskan). Cut-off values for the ELISA
assays were calculated as the mean specific OD plus 3 SD from
sera from non-immunized mice. Serum titers were established
as the reciprocal of the last dilution with an OD higher than
the cut-off.
Inhibition Assays
The capacity of antibodies to inhibit bacterial adhesion to
epithelial cells was evaluated. B. suisM1330 was grown overnight
in TSB at 37◦C with agitation and washed with sterile PBS. The
adequate volume of bacterial suspension, providing a multiplicity
of infection (MOI) of 100 for the subsequent cellular infection,
was incubated with decomplemented sera from immunized or
control mice (both at 1/10 dilution) for 1 h at 37◦C with gentle
shaking. After incubation, the bacterial suspension was used to
FIGURE 2 | Role of BtaF in B. suis intratracheal infection. BALB/c mice were inoculated by the intratracheal route with B. suis wt, B. suis 1btaF, or the complemented
strain. Mice from each group were euthanized at 7 and 30 days post-infection, and the lungs, spleens, and livers were removed. Dilutions of organs homogenates
were plated and CFU were counted. Values are means ± SD of duplicate measurements from three independent experiments. **p < 0.01, ***p < 0.001, and
****p < 0.0001 vs. wild type strain n.s., non-significant.
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FIGURE 3 | Properties of the B. suis BtaF recombinant protein. Schematic representation of the amino acid sequence of BtaF wt of B. suis (BR1846) and BtaF
recombinant protein (A). P: signal peptide; the black star indicates the predicted cleavage site of the signal peptide, MW, Molecular Weight. Purified BtaF recombinant
protein was subjected to SDS-PAGE and subsequent Coomassie Blue Staining (left), and also to Western blot using pooled sera from BtaF-immunized mice (right)
(B). Circular Dichroism spectrum of BtaF recombinant protein (C). Oligomeric state of BtaF recombinant protein in solution. BtaF was subjected to SEC coupled to a
light-scattering instrument connected in tandem to a differential refractometer detector. BtaF molecular weight was estimated by the relation of scattering/RI (D).
infect a confluent monolayer of A549 human lung epithelial cells
(ATCC CCL185) at a MOI of 100 in 96-well plates (5 × 104
cells/well). The cell culture was washed with sterile PBS and total
bacteria associated with the cells were determined by lysis with
0.2% Triton X-100 after 1 h of incubation at 37◦C in 5% CO2 and
plating serial dilutions. To quantify the number of intracellular
viable bacteria, the infected monolayers were incubated in
the presence of 100µg/ml gentamicin (Sigma Aldrich) to kill
extracellular bacteria (42). The number of adherent bacteria was
calculated as the difference between total bacteria associated to
the cells and intracellular bacteria.
The ability of antibodies to inhibit bacterial adhesion to
previously described BtaF ligands was also assayed. The assay was
performed essentially as described previously for testing bacterial
adhesion (20), except that bacteria were incubated with anti-
BtaF sera before ligand interaction. Briefly, 96-well plates (Nunc
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FIGURE 4 | Serum levels of BtaF specific antibodies after intranasal
immunization. Balb/c mice were immunized with BtaF+c-di-AMP or
saline+c-di-AMP at days 0, 7, and 14. Blood samples were collected at day
21 to determine anti-BtaF IgG, IgG1, and IgG2a antibody levels by ELISA.
Results are expressed as the mean OD450nm + SD (A) or as titers (B) of
values determined in duplicate for three independent experiments. Cut-off
values for the ELISA assay were calculated as the mean specific OD450nm +
3SD obtained for sera from non-immunized mice. Serum titers were
established as the reciprocal of the last dilution yielding an OD450nm higher
than the cut-off. ****p < 0.0001, and n.s. non-significant vs. non-immune.
Maxisorp) were coated overnight at 4◦C with 50 µl of 100µg/ml
solutions of each ligand (hialuronic acid, type I collagen or fetuin)
dissolved in PBS, and were then washed three times with PBS
to eliminate unbound ligand. Bacteria were grown overnight,
washed, and resuspended with the serum dilutions to achieve
a final concentration of 1 × 109 CFU/ml. Pooled sera from
each immunization group (BtaF+c-di-AMP or c-di-AMP, 21
days post-immunization) and from non-immunized mice (pre-
immunization samples) were used (1:10 dilution in sterile PBS).
After 1 h incubation at 37◦C, 50 µl of bacterial suspensions
were added to each ligand-coated well and incubated at 37◦C
for 3 h. After incubation, wells were washed three times with
PBS to remove non-adherent bacteria, and were then incubated
with 0.05% trypsin−0.5% EDTA for 10min at 37◦C to harvest
adherent bacteria. Serial dilutions of the bacterial suspensions
were done and plated on TSB agar for CFU counting.
Opsonophagocytosis Assay
Brucella suis was grown overnight in TSB, washed with sterile
PBS and resuspended in a 1:10 dilution of pooled sera from each
immunization group (BtaF+c-di-AMP or saline+c-di-AMP) or
from non-immunized mice. After 1 h incubation at 37◦C, the
bacterial suspension was used to infect murine macrophages
(RAW 264.7 cell line) at a MOI of 100 in 96-well plates (5 × 104
cells/well) for 2 h at 37◦C (time 0 p.i.). Macrophages were used
either untreated or pretreated for 24 h with recombinant murine
IFN-γ (100 IU/ml). The cell culture was washed with sterile
PBS and cultured with complete medium containing 50µg/ml
of gentamicin for 2 h to kill extracellular bacteria. To determine
the number of intracellular bacteria cells were washed three times
with sterile PBS and lysed with 0.2% Triton X-100, and serial
dilutions of the lysates were plated on TSA for CFU counting.
In vitro Cellular Responses
One week after last immunization, mice were euthanized with
a lethal dose of ketamine and xylazine (400 and 32 mg/kg,
respectively) and spleens and lungs were removed. Lung cells
were obtained after incubation with 200U/ml type IV collagenase
supplemented with 5% Fetal Bovine Serum (FBS) and 20 U/ml
Deoxyribonuclease I for 20min at 37◦C. Lung and spleen cells
were cultured in a 96 wells plate at 1 × 106 cells/well or 48 wells
plate in duplicate at 4 × 106 cells/ml, respectively, in RPMI 1640
supplemented with 10% FBS, 1mMpyruvate, 2mML-glutamine,
100 U/ml penicillin and 100µg/ml streptomycin. Lung cells were
stimulated with 10µg/ml BtaF protein or complete medium
alone, while spleen cells were stimulated with 10µg/ml BtaF
protein, 5µg/ml Concanavalin A (ConA), or complete medium
alone. After 72 h of incubation at 37◦C and 5% CO2, cell culture
supernatants were collected and gamma interferon (IFN-γ),
interleukin 2 (IL-2), IL-5, and IL-17 production was analyzed
by commercial sandwich ELISA, according to the manufacturer’s
instructions (BD Bioscience).
Flow Cytometry Analysis
Cervical lymph nodes cells (1 × 106 cells/well) from immunized
and control mice were cultured in 96-well plates with BtaF
(10µg/ml) in RPMI 1640 supplemented with 10% FBS, 1mM
pyruvate, 2mM L-glutamine, 100 U/ml penicillin, and 100µg/ml
streptomycin for 16 h at 37◦C and 5% CO2. After stimulation,
cells were stained with APC-anti-mouse CD3 monoclonal
antibody (mAb) (clone 17A2, Thermo Fisher Scientific), PE-
CyTM5-anti-mouse CD4mAb (clone RM4-5, BD Bioscience),
PE-CyTM7-anti-mouse CD8mAb (clone 53-6.7, BD Bioscience),
PE-anti-mouse CD44mAb (clone IM7, BD Bioscience), and
FITC-anti-mouse CD62LmAb (clone MEL-14k, BD Bioscience).
Flow cytometry analysis was performed using FACSAriaII flow
cytometer (BD Bioscience) and further analyzed using FlowJo 7.5
software (TreeStar Inc.).
Delayed-Type Hypersensitivity (DTH) Test
One week after last immunization, mice were injected
intradermally in one footpad with 10 µg of BtaF in 10 µl
of PBS, and in the contralateral footpad with an equal volume of
PBS as negative control. The footpad thickness was measured 48
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FIGURE 5 | Anti-BtaF IgA antibodies in sera and mucosal samples. BALB/c mice were immunized with BtaF+c-di-AMP (BtaF) or saline+c-di-AMP (saline) at days 0,
7, and 14. One week after last immunization serum, saliva, feces, vaginal lavage, and bronchoalveolar (BAL) fluids and lung homogenates were obtained, and specific
IgA antibody levels were measured by ELISA. Results are expressed as the mean OD450nm + SD of three independent experiments. The asterisks indicate significant
differences between the immunized group and the saline group. **p < 0.01.
and 72 h later by using a digital caliper. At each time point, the
mean increase in footpad thickness was expressed as the relation
between the BtaF footpad and the saline footpad.
Protection Assessment
At 15 days after last immunization, mice immunized with BtaF
plus c-di-AMP and the control group (saline) were challenged
through the intratracheal or the intragastric route with 6.5 ×
104 or 4 × 107 CFU of B. suis M1330, respectively. Three weeks
after challenge, mice were euthanized, and lungs and spleens (for
the intratracheal challenge) or the spleens (for the intragastric
challenge) were aseptically removed. Dilutions of homogenized
organs were plated on TSA and incubated for 3 days at 37◦C. The
number of CFU was counted and results were represented as the
mean CFU/ml± SEM per group.
Statistical Analysis
Data were analyzed using analysis of variances (ANOVA).
Multiple comparisons between all pairs of groups were made
with the Tukey’s post-test, and those against a control group
were made with Dunnett’s post-test. A p < 0.05 was considered
as statistically significant. All statistical analyses were performed
with the GraphPad software (San Diego, CA).
RESULTS
Kinetics of B. suis Infection in Lungs and
Dissemination to Peripheral Organs
In order to evaluate the impact of BtaF on the course of
respiratory B. suis infection, we first characterized the mouse
model of intratracheal infection with B. suis at early (1 and 7
days) and later times (30 days) post-infection (p.i.). At these time
points CFU numbers were determined in lung, liver, and spleen
homogenates. As shown in Figure 1, the pulmonary bacterial
burden increased significantly (1.55 log) during the first week p.i.
but significantly decreased at 30 days p.i. (1.81 log as compared
to 7 days p.i.). B. suis could disseminate from the initial infection
site and was first recovered from spleen and liver at 7 days
p.i. The bacterial load in spleen significantly increased at 30
days p.i. as compared to previous days (p < 0.001, T-test vs.
7 days p.i.). However, the bacterial burden in liver remained
constant (p > 0.05).
BtaF Is Required for Full Virulence of
B. suis in an Intratracheal Infection
It was previously shown that BtaF is required for a successful
infection of B. suis administered through the oral route in mice
(20). To evaluate if BtaF has a similar impact in a respiratory
model of infection, groups of 15 mice were anesthetized and
inoculated through the intratracheal route with B. suis wt, the
1btaF mutant, or the 1btaF complemented strain. Five mice
from each group were sacrificed at 1, 7 and 30 days p.i., which
represent early and stabilized infection times, and the bacterial
burden in spleen, lungs and liver was measured. At 1 day p.i., no
differences in lungs burden were found between the wt strain and
the 1btaF mutant (data not shown).
At 7 and 30 days p.i., the lung infection with B. suis1btaF was
reduced by 0.28 log and 1 log, respectively, compared with the wt
strain (Figure 2). Although no differences in CFU counts were
detected in spleen at 7 days (data not shown), a reduction of 0.54
log was observed in this organ at 30 days p.i. with B. suis 1btaF.
No differences were observed in liver colonization between the
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FIGURE 6 | Neutralizing and opsonizing capacity of BtaF-specific antibodies.
B. suis wt was incubated with serum from mice immunized with either
BtaF+c-di-AMP (BtaF) or saline+c-di-AMP (Adjuvant) before co-culture with a
confluent monolayer of A549 cell line. Total bacteria associated to the cell
monolayer were determined (A). Similarly, bacteria were incubated with sera
from mice of the BtaF+c-di-AMP (BtaF) or saline+c-di-AMP (Adjuvant)
immunization groups or from non-immunized mice (NI) before addition to wells
coated with type I collagen, hialuronic acid (HA) or fetuin. Adherent bacteria
recovered after trypsinization were determined (B). Bacteria were preincubated
as described and added to murine macrophages for 2 h. Macrophages were
used either untreated or pretreated for 24 h with recombinant murine IFN-γ.
After treatment with gentamicin for 2 h to kill extracellular bacteria, cells were
lysed and the lysates were plated for CFU counting (C). Results are expressed
as mean ± SD of duplicate measurements from three independent
experiments. *p < 0.05, **p < 0.01 vs. Adjuvant group (A) or NI group (B,C).
wt and mutant strains. In all cases, no statistical differences were
observed between the wt and complemented strains, except for
lung tissue at 30 days p.i., in which only partial complementation
was observed.
These results show that BtaF is involved in Brucella lung
colonization and dissemination to spleen and is required
for full virulence of B. suis in mice infected through the
intratracheal route.
Nasal Immunization With BtaF Plus
c-di-AMP Elicits Systemic and Mucosal
Humoral Immune Responses
Given the role of BtaF in B. suis infection through the respiratory
route, we decided to evaluate the BtaF potential as an antigen for
nasal vaccination. To achieve this aim, we designed, expressed
and purified most of the BtaF passenger domain as a soluble
trimeric protein. The GCN4tri sequence was fused to the C-
terminal portion of BtaF in order to help the protein to form
a trimer (37) and keep its native conformation (Figure 3A).
Analysis through SDS-PAGE of the two step purified BtaF
trimeric recombinant protein showed that the protein used in
the following immunizations was highly purified (Figure 3B,
left panel). Moreover, Western blot analysis indicated that the
protein was immunogenic in mice (Figure 3B, right panel).
Circular dichroism indicated that the secondary structure of BtaF
is mainly α-helix (Figure 3C), and Static Light Scattering coupled
to a Size-Exclusion Chromatography (SEC-SLS) indicated that
recombinant BtaF had an experimental molecular weight of
67.7 ± 0.7 kDa in solution, which is similar to the theoretical
molecular weight for the trimer of 66.6 kDa estimated by the
ProtParam tool from ExPASy (39) (Figure 3D). To evaluate if
BtaF is a potential antigen for nasal vaccination, mice were
separated into two groups (n = 5) and were immunized by
the nasal route with BtaF (10 µg) plus c-di-AMP (10 µg) or
saline plus c-di-AMP (10 µg) at days 0, 7, and 14. Specific anti-
BtaF antibodies were measured in different samples. Significant
differences in anti-BtaF IgG (p < 0.0001 vs. non-immune; p
< 0.0001 vs. saline) (Figure 4A) and anti-BtaF IgA levels (p <
0.01 vs. saline) (Figure 5), were detected at 21 days after first
immunization, reaching median titers of 204,800 and 12,800,
respectively. To further investigate the humoral response induced
by nasal administration of BtaF, the titers of specific serum IgG
subclasses (IgG1 and IgG2a) were determined. As shown in
Figure 4B, a mixed Th1-associated IgG2a and Th2-associated
IgG1 response was observed in the sera of BtaF immunized mice.
On the other hand, nasal immunization with BtaF+c-di-AMP
triggered a significant induction of specific mucosal IgA antibody
production in saliva, feces, vaginal lavage, BAL, and lungs
compared with the control group (saline+c-di-AMP) (Figure 5).
To analyse the functionality of the serum specific antibodies
elicited by nasal immunization, its capacity to inhibit bacterial
adhesion to epithelial cells and to previously described BtaF
ligands was evaluated. Serum antibodies from BtaF+c-di-AMP
immunized mice could significantly reduce bacterial adhesion
to A549 epithelial cells in comparison with serum from the
control group (Figure 6A). In addition, these antibodies were
also able to reduce significantly the binding of B. suis to
fetuin and also reduced, albeit non-significantly, its binding
to hialuronic acid (Figure 6B). In vitro, the phagocytosis of
B. suis by murine macrophages was significantly increased
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when bacteria were preincubated with sera from the BtaF+c-
di-AMP group as compared to preincubation with sera from
non-immunized mice (Figure 6C). In contrast, preincubation
with sera from the saline+c-di-AMP group had no effect. IFN-
γ-activated macrophages killed internalized bacteria at similar
levels regardless of the preincubation serum.
Nasal Immunization With BtaF Plus
c-di-AMP Induces BtaF-Specific Cellular
Immune Responses
It has been demonstrated that the cellular immune response
is important in protection against Brucella infection (43–45).
Thus, in order to characterize the cellular immune response
elicited by nasal immunization with BtaF, lung and spleen
cell suspensions from BtaF immunized and control mice were
cultured ex vivo with BtaF or with complete culture medium
alone (RPMI) as control. As shown in Figure 7A, spleen cells
from BtaF immunized mice stimulated ex vivo with BtaF
secreted significantly higher levels of IL-2, IL-5, IL-17, and IFN-
γ compared with the control group. ConA, used as a positive
control, induced the production of the corresponding cytokines
in all groups.
To corroborate the induction of BtaF-specific Th1 responses,
as suggested by the results described above, the delayed type
hypersensitivity (DTH) response was determined in immunized
mice. One week after last immunization, mice were injected
intradermally in one footpad with BtaF and in the contralateral
footpad with an equal volume of saline as negative control.
As shown in Figure 7B, a BtaF specific DTH response was
observed at 48 and 72 h in BtaF immunized mice. Interestingly,
the stimulation of the lung cells with BtaF induced a high
production of IFN-γ when compared with the cells of the
control group (Figure 7C). This result suggests that the nasal
vaccine induces a strong cellular specific immune response in
lung against the BtaF antigen. Altogether these results indicate
that nasal immunization with BtaF plus c-di-AMP induces
specific cellular immune response, both at the mucosal and
systemic level.
Administration of BtaF Plus c-di-AMP
Promotes Ag-Experienced Effector CD4+
T Cells
To determine whether T cells from immunized mice develop
into memory T cells or maintain an activated phenotype, the Ag-
experienced T cells were identified by the expression of CD44 (46,
47) in cervical draining lymph nodes from immunized mice after
in vitro re-stimulation. Memory T cells can be further divided
based on CD62L (L-selectin) expression into central memory T
cells (CD62Lhigh) and effector memory T cells (CD62Llow) (48).
Then, the percentage of cells expressing CD44 and the activation
marker CD62L was analyzed in the CD4+ T cell population
(Figure 8A).
Phenotypic analysis showed that CD4+ T cells
from mice nasally immunized with BtaF+c-di-AMP
exhibited a significantly higher proportion of the
CD44high/CD62Lhigh(5.86%) phenotype and a tendency,
albeit not significant, toward a higher percentage of
CD44high/CD62Llow (5.54%) subpopulation as compared
to cells from control group (3.77 and 4.32%, respectively;
Figure 8B). These results indicate that Ag-experienced CD4+
T cells are maintained mainly as central memory cells in mice
immunized with BtaF plus c-di-AMP.
Nasal Immunization With BtaF Plus
c-di-AMP Confers Protection Against
Intragastric Infection
Nasal immunization with BtaF+c-di-AMP elicited Ag-specific
cellular and humoral immune responses both systemically and
at mucosal surfaces. To assess if such immune responses
conferred protection against respiratory challenge, immunized
mice were infected through the intratracheal route with virulent
B. suis wt, and 3 weeks post-challenge the lung and splenic
loads of bacteria were determined. As shown in Table 1,
immunization with BtaF protein did not confer any protection
against B. suis respiratory challenge, as no significant differences
were observed in organs colonization between immunized and
control groups.
Taking into account that we previously demonstrated that
BtaF is required for full virulence after intragastric infection (20)
and that in the present study nasal immunization with BtaF
generated a humoral immune response in the gastro-intestinal
mucosae, we evaluated the potential protection conferred by
nasal immunization with BtaF against intragastric challenge with
B. suis wt. As shown in Table 1, at 3 weeks post-challenge
immunized mice showed a significant clearance (p < 0.0001) of
B. suis from spleen compared with the control group, achieving
a 3.28 log reduction in CFU counts. These results indicate
that nasal immunization with BtaF recombinant protein induces
protection against B. suis infections acquired through the gastro-
intestinal mucosae.
DISCUSSION
Nasal vaccination is a desirable method to induce immunity
against infectious diseases in humans as well as animals. Not
only it is easily administered compared to other immunization
methods, as it does not need needles, but it also induces mucosal
as well as systemic immunity. Although Brucella infection is
acquired through mucosal routes, brucellosis is a systemic
disease. After adhesion and penetration of the epithelial barrier,
bacteria spread to the reticuloendothelial system, and affect
different organ systems. Therefore, an effective nasal brucellosis
vaccine must induce mucosal immunity able to stop Brucella at
the mucosal surface, and must also induce systemic immunity to
eliminate the infected cells.
Nasal vaccines based on live attenuated Brucella strains have
been tested in some studies to evaluate protection against
mucosal infection, and were ineffective (28, 35). In addition,
the risk of human infection and illness caused by attenuated
strains prevents its use in humans. Although swine brucellosis
is a worldwide distributed zoonotic disease, there are no vaccines
approved for use in humans or pigs to protect against infection
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FIGURE 7 | Specific cellular immune response in BtaF immunized mice. Lung cells and splenocytes from immunized and control mice were cultured in duplicate with
BtaF, ConA, or medium. At 72 h post-stimulation culture supernatants were harvested from splenocytes to measure levels of IL-2, IL-5, IL-17, and IFN-γ (A), and from
lung cells to measure IFN-γ (C) by ELISA. Results are expressed as the mean concentration (pg/ml) ± SD of duplicate measurements from three independent
experiments. Up arrowheads indicate significant differences between BtaF and control condition (medium) in the vaccinated group (∧p < 0.05; ∧∧p < 0.01; ∧∧∧∧p <
0.0001). Asterisks indicate significant differences between vaccinated and control mice for the same stimulus (**p < 0.01 and ****p < 0.0001). To perform the DTH
test (B), 1 week after last immunization mice were injected intradermally in one footpad with 10 µg BtaF and in the contralateral footpad with an equal volume of
saline. The footpad thickness was measured 48 and 72 h later. The mean increase in footpad thickness was expressed as the relation between the BtaF footpad and
the saline footpad. *p < 0.05 and **p < 0.01 vs. saline at 48 and 72 h, respectively.
caused by B. suis. Moreover, there are no approved vaccines
to prevent human infections by any Brucella species. In this
study, we evaluated the role of the BtaF adhesin from B. suis
during intratracheal infection in the mouse model and evaluated
the protection capacity of BtaF recombinant protein as a novel
acellular vaccine against mucosal challenge. Designing strategies
that interfere with bacterial adhesion to host components may
also help to prevent disease progression.
The inhalation of contaminated aerosols with Brucella spp.
is an important cause of human and animal brucellosis. Most
studies about respiratory infection have focused on infections
by B. abortus and B. melitensis, with only one study describing
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FIGURE 8 | Phenotypic analysis of memory CD4+ T cells by flow cytometry. Cervical lymph nodes cells (1 × 106 cells/well) from immunized and control mice were
cultured in 96-well plates with BtaF (10µg/ml) in complete medium for 16 h. The percentage of CD4+ T cells expressing the CD62L and CD44 markers was
determined by flow cytometry. Subpopulations determined for each experimental group are shown in representative dotplots (A), and their mean proportions (±SD)
are shown in the bar graph (B). **p < 0.01 vs. saline.
a mouse model of infection with aerosolized B. suis (49).
Despite the valuable information provided by that study, there
is no knowledge regarding bacteria replication and systemic
dissemination during the first week after B. suis airborne
infection. In this study we used a murine model of intratracheal
infection with B. suis to investigate the importance of the
BtaF adhesin at early and late time points post-infection. After
intratracheal infection, the pulmonary load of B. suiswt increased
1.55 log during the first week, but decreased to almost the initial
inoculum at 30 days p.i. The pathogen could disseminate early
from the initial infection site in the lungs, since it was recovered
from spleen and liver at 7 days p.i. We recently demonstrated
that B. abortus persists in the mouse lung without modifying
its initial load during the first week after intratracheal infection
(36). These results differ from those obtained in the present study
and demonstrate that B. suis causes a more acute infection than
B. abortus in the lung. When mice were infected with the B. suis
1btaF mutant no differences in lung burden were observed as
compared with the wt strain at 1 day p.i. (data not shown).
However, at later times there was a significant decrease in the
burden of bacteria in lungs and spleen in animals infected with
the mutant strain as compared to those infected with the wt
strain. These results agree with those of a previous study showing
that the deletion of BtaF reduces the splenic load of B. suis in mice
infected by the intragastric route (20). Recently it was shown that
after being inhaled, most Brucella bacteria are captured by the
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Lung 3.841 ± 0.168 3.843 ± 0.213 0.002 n.s.
Spleen 4.653 ± 0.114 4.538 ± 0.194 0.115 n.s.
Intragastric challenge
Spleen 4.471 ± 0.622 1.185 ± 0.386 3.285 P < 0.0001
Mice from BtaF+c-di-AMP and saline groups were challenged through the intratracheal
or intragastric route with B. suis wt. CFU were measured in lungs and/or spleens at 20
days post-challenge. Results are expressed as mean ± SD of duplicate measurements
from two independent experiments.
alveolar macrophages (50). In the present study, BtaF deletion
did not affect the adherence and infection of B. suis to primary
murine alveolar macrophages (data not shown). Our results
suggest that after being inhaled, most of the B. suis bacteria are
phagocytosed by alveolar macrophages, and that BtaF does not
have a relevant role in this interaction. In line with these results, it
was previously shown that the adhesion and intracellular survival
of B. suis in murine macrophages was not affected by the absence
of the BmaC adhesin (19). At later times after intratracheal
infection, the BtaF adhesin could participate in the interaction
of the bacterium with other lung non-phagocytic cells, such
as alveolar epithelial cells. We have previously demonstrated
that B. suis adheres and infects human alveolar epithelial cells
(A549 cell line) (51) and that BtaF deletion reduces bacterial
adhesion to these cells (20). Moreover, BtaF participated in the
resistance of B. suis to the bactericidal activity of complement, an
important component of an efficient immune response against
certain pathogens. This resistance could explain the impairment
of 1btaF mutant to achieve the same burden as the wt strain
in peripheral organs and the incapability to efficiently persist in
lungs. Together our results show that the BtaF adhesin is required
for full virulence of B. suis after intratracheal infection.
Taking into account the relevance of the BtaF adhesin in
the persistence and dissemination of B. suis after inoculation
by mucosae, in this study we evaluated the immunogenic and
protective potential of the recombinant BtaF adhesin as a nasal
subunit vaccine. BtaF is a trimeric autotransporter protein that
contributes to adhesion to epithelial cells and many components
of the ECM (20). The BtaF recombinant protein was designed
to be expressed as a soluble trimeric protein without the C-
terminal β-barrel translocator domain. Using the BtaF domain
that is exposed on the bacterial cell surface in its native (and
trimeric) structure, combined with the appropriate adjuvant
(see below), was probably an important factor to achieve a
protective immune response against B. suis. In line with this,
some proteins from the autotransporter families were shown to
be promising antigens for the design of vaccines against other
pathogens, including Bordetella pertussis (52, 53), Haemophilus
influenza (54), Haemophilus ducreyi (55), Shigella (56), and
Enterotoxigenic Escherichia coli (ETEC) (57). In all these cases,
a recombinant protein corresponding to the autotransporter
passenger domain has been used, reinforcing the potential of this
protein family as subunit vaccines.
Subunit vaccines require a good immunogen and an
appropriate adjuvant. In this study, mice were vaccinated by
the nasal route with BtaF recombinant protein plus c-di-
AMP. Several studies demonstrated that c-di-AMP, a cyclic di-
nucleotide, exerts strong adjuvant activities when it is used
in mucosal vaccine formulations. c-di AMP is able to activate
dendritic cells, promoting both local and systemic immune
responses and stimulating a balanced T helper (Th1/Th2/Th17)
immune response (30–32, 34). Moreover, administration of c-di-
AMP by mucosal route also induces a strong humoral immune
response accompanied by secretory IgA detected both locally, as
well as at distantmucosal sites (32, 33). In line with these previous
reports, high levels of anti-BtaF IgG and IgA were detected in
serum of BtaF plus c-di AMP immunized mice, which could also
partially reduce B. suis adhesion to A549 cells. The fact that only
a partial reduction was achieved probably relates to the existence
of numerous adhesins on the surface of B. suis (19–21), which
may confer redundant binding capacities to the pathogen. In
particular, BmaC and BtaE adhesins have been shown to mediate
B. suis adhesion to A549 cells. In addition, anti-BtaF sera were
also able to reduce significantly the bacterial binding to fetuin, a
previously described BtaF ligand (20). Of note, the phagocytosis
of B. suis by murine macrophages was enhanced by the previous
opsonization of the bacterium with serum antibodies against
BtaF. Since IgG subclass responses are determined by the
pattern of cytokines secreted by CD4+T cells, we measured
the titers of antigen-specific IgG1 and IgG2a antibodies. BtaF-
vaccinated mice exhibited a mixed IgG1/IgG2a response to BtaF.
IgG2a antibodies are important for defense as they activate
in phagocytes a broad spectrum of antimicrobial responses
(e.g., opsonization and release of inflammatory mediators). In
addition, nasal immunization elicited a significant production
of specific IgA antibodies at the respiratory, gastrointestinal and
genital mucosae. These antibodies could contribute to reduce the
initial adhesion of the bacteria to the mucosal epithelium.
Due to its intracellular residence, the protective immune
response against Brucella requires cell-mediated-immunity,
which includes IFN-γ-producing CD4+ T cells (58), while the
role played by CD8+ cells in protection is less clear. Some studies
concluded that CD8+ T cells are critical for the resolution of
infection, whereas others suggested that they are dispensable
(44, 59, 60). In our study, nasal vaccination with BtaF plus c-
di-AMP induced a Th1 response that could be measured in
vivo and in vitro. Splenocytes and lung cells of immunized mice
produced high levels of IFN-γ after in vitro stimulation with the
antigen, indicating the generation of a Th1 response both locally
and systemically. To further characterize the T cells involved in
the cellular responses to BtaF, the antigen-experienced T cells
were identified by the expression of the memory marker CD44
and the lymph node homing molecule CD62L. BtaF vaccinated
mice exhibited a low but significant increase in the antigen
specific central memory CD4+ T cell population in cervical
lymph nodes. Moreover, nasal vaccination with BtaF plus c-
di-AMP also induced the Th17 subset. The strong production
of IL-17 by the spleen cells of BtaF vaccinated mice may be
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associated to both the adjuvant (32–34) and the mucosal route
of administration (50, 60–62).
To determine whether the immune response triggered by
our vaccine can protect against Brucella infection, vaccinated
and unvaccinated mice were challenged through the intragastric
route with B. suis M1330. The criterion used to determine if a
vaccine induces a protective response against Brucella spp. is the
reduction of the bacterial load in spleen of vaccinated mice as
compared to unvaccinated mice (61, 63, 64). The BtaF vaccine
proved to exert high levels of protection against intragastric
B. suis infection. This vaccine reduced splenic colonization by
3.28 log in challenged mice, which is a high level of protection
as compared to other experimental Brucella vaccines based on
single antigens. Although the protective mechanisms against
B. suis oral infection are not well-established, previous studies
showed that Th17 cells have a protective role in oral RB51
(vaccine strain) and also in recombinant unlipidated Omp19
mice vaccination against B. abortus oral infection, suggesting
that Th17 cells may act synergistically with Th1 cells to
achieve protection through vaccination (61, 62). The protection
conferred by the BtaF nasal vaccine could be due to both
the humoral immune responses elicited in the gastrointestinal
mucosa as well as the mixed Th1/Th17 profile generated during
the immunization.
Unlike what was observed for oral infection, nasal vaccination
with BtaF did not protect against B. suis respiratory infection.
No differences were observed in bacterial load in spleen
or lung between vaccinated and unvaccinated mice after
intratracheal challenge. Recent studies suggest that the immune
response necessary to protect against Brucella spp. depends
on the type of vaccine and its composition, the route of
vaccination and the route of challenge (59–62). In the case
of pulmonary brucellosis, protection is determined mainly by
the delivery method and vaccine composition (28, 35, 60).
Parenteral vaccination against brucellosis proved ineffective
for brucellae clearance from lungs (65, 66). Several studies
assayed the efficacy of nasal vaccination with attenuated
strains currently used for livestock parenteral vaccination.
Nasal vaccination with RB51 did not induce respiratory
protection against nasal B. abortus challenge (35). Similarly,
nasal administration of B. abortus S19 vaccine did not
induce significant clearance of B. abortus from spleen upon
intranasal challenge but induced significant clearance of bacteria
from lungs (35). The most successful approaches regarding
protection against pulmonary infection consisted in oral and
nasal administration of high doses (109 CFU) of inactivated or
attenuated strains (60, 63) that implies, in the case of attenuated
strains, the risks associated with its manipulation, stability
and administration.
Apparently, according to our results, the activation of specific
humoral and cellular immune responses in the site of entry
and the generation of memory T cells are sufficient to protect
against oral infection but not against respiratory infection
with B. suis. Currently little is known about the immune
response needed to protect the lungs from a respiratory infection
by Brucella. Recently, Clapp et al. (60) demonstrated that
nasal B. melitensis 1znuA vaccination protects the lung from
B. melitensis respiratory infection, and that CD8+ T cells, but not
CD4+ and Th17 cells, are essential for this protection. In contrast
with this study, Yinst et al. (59) demonstrated that CD8 knockout
mice are protected from nasal challenge after oral vaccination
with a live attenuated strain of B. melitensis.
In conclusion, our results demonstrate that nasal vaccination
with BtaF plus c-di-AMP confers protection against intragastric
challenge with B. suis by inducing a specific humoral immune
response both locally and systemically, central memory CD4+
T cells, and a mixed T helper response with a strong induction
of the Th1 phenotype. This is the first demonstration of
a nasal subunit vaccine capable to elicit a high level of
protection in mice infected through the oral route. In addition,
according to the results of this study, it is unlikely that
a single antigen could confer protection against respiratory
infection with Brucella spp. An approach to identify antigens
that induce synergistically protective immune responses must
be considered.
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